Growth and Contraction in the Pharmaceutical and Health Sector: A 2024-2025 Outlook

Differentiation Observed in the Pharmaceutical and Health Sector

Sales data for Turkey’s pharmaceutical and health sector for the 2024/09 – 2025/09 period reveals a clear separation within the industry. While some companies show growth of up to 20%, others face double-digit contraction. This situation highlights the lack of a stable growth rhythm in the sector and indicates that the product portfolio and market dynamics yield different results for each company.

Growth Indicators

In particular, Tapdi Tınaztepe and Türk İlaç ve Serum companies stand out by significantly increasing their sales. Tapdi Tınaztepe raised its sales from 2.03 billion TL to 2.44 billion TL, marking an increase of 20.09%, while Türk İlaç ve Serum reached 2.69 billion TL with a 19.11% increase.

On the other hand, MLP Sağlık reached 39.22 billion TL with a 6.73% growth, while Lokman Hekim Sağlık increased to 2.95 billion TL with a 6.58% rise. This situation indicates that even large-scale companies are experiencing growth, but it remains limited.

Contractions and Challenges

Companies experiencing significant sales declines are being monitored closely. Eczacıbaşı İlaç declined by 18.13% to 6.90 billion TL, while Deva Holding fell 5.92% to 13.75 billion TL. Seyitler Kimya experienced the most remarkable contraction in the sector with a 24.55% drop to 165.2 million TL.

General Assessment

In conclusion, it is clear that there is no one-dimensional outlook in Turkey's pharmaceutical and health sector. The coexistence of rapidly growing companies alongside those facing significant sales declines highlights the contradictory dynamics within the sector. This situation strengthens the need for detailed company-specific analysis when evaluating sector performance.